Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Su-Pin Choo

Showing results (101-110 of 108) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 108 results.
Nature Communications|June 8, 2019
PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoproteinMin Thura, Abdul Qader Al-Aidaroos, Abhishek Gupta, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 2, 2022
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumorsStephen L Chan, Martin Schuler, Yoon-Koo Kang, et al.
Cancer Discovery|October 3, 2019
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular CarcinomaRichard D Kim, Debashis Sarker, Tim Meyer, et al.
Nature Genetics|November 5, 2013
Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancersWaraporn Chan-On, Maarja-Liisa Nairismägi, Choon Kiat Ong, et al.
Liver Cancer|July 9, 2021
Real-World Data on Clinical Outcomes of Patients with Liver Cancer: A Prospective Validation of the National Cancer Centre Singapore Consensus Guidelines for the Management of Hepatocellular CarcinomaXin Hui Chew, Rehena Sultana, Eshani N Mathew, et al.
Gut|August 26, 2021
Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibitionRaghav Sundar, Kie-Kyon Huang, Vikrant Kumar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2018
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular CarcinomaPierce K H Chow, Mihir Gandhi, Say-Beng Tan, et al.
Cancer Discovery|July 2, 2017
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of CholangiocarcinomaApinya Jusakul, Ioana Cutcutache, Chern Han Yong, et al.
Pageof 11

Showing results (101-110 of 108) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 108 results.
Nature Communications|June 8, 2019
PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoproteinMin Thura, Abdul Qader Al-Aidaroos, Abhishek Gupta, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 2, 2022
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumorsStephen L Chan, Martin Schuler, Yoon-Koo Kang, et al.
Cancer Discovery|October 3, 2019
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular CarcinomaRichard D Kim, Debashis Sarker, Tim Meyer, et al.
Nature Genetics|November 5, 2013
Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancersWaraporn Chan-On, Maarja-Liisa Nairismägi, Choon Kiat Ong, et al.
Liver Cancer|July 9, 2021
Real-World Data on Clinical Outcomes of Patients with Liver Cancer: A Prospective Validation of the National Cancer Centre Singapore Consensus Guidelines for the Management of Hepatocellular CarcinomaXin Hui Chew, Rehena Sultana, Eshani N Mathew, et al.
Gut|August 26, 2021
Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibitionRaghav Sundar, Kie-Kyon Huang, Vikrant Kumar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2018
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular CarcinomaPierce K H Chow, Mihir Gandhi, Say-Beng Tan, et al.
Cancer Discovery|July 2, 2017
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of CholangiocarcinomaApinya Jusakul, Ioana Cutcutache, Chern Han Yong, et al.
Pageof 11